{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:50:08Z","timestamp":1794487808679,"version":"4.9.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Ophthalmol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the effectiveness and safety of oral propranolol for the treatment of ocular adnexal infantile hemangiomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>retrospective observational cohort study. Propranolol was administered at an initial oral dose of 1 mg\/kg and subsequently increased to 2 mg\/kg for 1 year. Outcomes were evaluated by comparing pre- and post-treatment clinical findings, contrast-enhanced ultrasound (CEUS) findings and\/or orbital magnetic resonance imaging findings from baseline to 3, 6, 9, 12, 24, and 48 weeks. Regression was graded as follows: satisfactory when 90% and above of the baseline lesion volume and extension decreased, acceptable when 50 to 90%, mediocre when 30 to 50%, poor less than 30%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-four patients were included in this study. The mean age at presentation was 4 \u00b1 1 week. Sixteen (71%) patients were females and 7 (29%) were males. The mean follow-up duration was 18 \u00b1 3 months. Therapy was started for of 23\/24 patients at 5 weeks old, of 1\/24 started at 9 weeks of age. The median age was 5,16 weeks. Sixteen patients (66%) had satisfactory resolution between 3 and 6 weeks, 5 (20%) after 9 weeks, and 3 (12%) after 12 weeks. One patient (5%) had a mediocre response after 24 weeks. One patient withdrew from therapy because of hypoglycemia, which was successfully managed as an outpatient. No significant adverse reactions, such as bradycardia, hypotension, bronchospasm, or congestive heart failure, were detected in this cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study indicates that the real-life use of oral propranolol for infantile hemangioma yields a high success rate with a lower morbidity than previously reported, particularly when managed by a proficient and multidisciplinary team.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fopht.2025.1493171","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:10:38Z","timestamp":1746418238000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-life efficacy and safety of oral propranolol for ocular adnexal infantile hemangiomas: observational cohort study"],"prefix":"10.3389","volume":"5","author":[{"given":"Stefano","family":"Malvindi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sammarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Elefante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Lanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cicala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Iuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mariniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"D\u2019Aponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Strianese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03650.x","article-title":"Infantile hemangiomas: a challenge in pediatric dermatology","volume":"24","author":"Schwartz","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile hemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jpeds.2008.05.043","article-title":"Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants","volume":"153","author":"Drolet","year":"2008","journal-title":"J Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00626.x","article-title":"Infantile hemangiomas: how common are they? A systematic review of the medical literature","volume":"25","author":"Kilcline","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.12.003","article-title":"Prevalence and characteristics of hemangiomas in young children","volume":"149","author":"Hoornweg","year":"2005","journal-title":"Ned Tijdschr Geneeskd"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2014.170.issue-4","article-title":"Prospective study of infantile hemangiomas: incidence, clinical characteristics and association with placental anomalies","volume":"170","author":"Munden","year":"2014","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2767","article-title":"Growth characteristics of infantile hemangiomas: implications for management","volume":"122","author":"Chang","year":"2008","journal-title":"Pediatrics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.07.061","article-title":"Late growth of infantile hemangiomas in children >3 years of age: A retrospective study","volume":"80","author":"O'Brien","year":"2019","journal-title":"J Amer Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318208d2ac","article-title":"Untreated hemangiomas: growth pattern and residual lesions","volume":"127","author":"Bauland","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.12.1567","article-title":"Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex","volume":"138","author":"Chiller","year":"2002","journal-title":"Arch Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jum.15489","article-title":"Subclinical ultrasound characteristics of infantile hemangiomas that may potentially affect involution","volume":"40","author":"McNab","year":"2020","journal-title":"J Ultrasound Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijporl.2017.08.035","article-title":"Role of imaging in the diagnosis of parotid infantile hemangiomas","volume":"102","author":"Weber","year":"2017","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1573396316666200508100038","article-title":"Infantile hemangioma: an updated review","volume":"17","author":"Leung","year":"2021","journal-title":"Curr Pediatr Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12575","article-title":"Pediatric congenital cerebrovascular anomalies","volume":"29","author":"Goyal","year":"2019","journal-title":"J Neuroimaging."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.208884","article-title":"Propranolol for infantile hemangiomas: a review","volume":"96","author":"Starkey","year":"2011","journal-title":"Arch Dis Child"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13925","article-title":"Periocular infantile hemangiomas: Characteristics, ocular sequelae, and outcomes","volume":"36","author":"Zhao","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2011-3683","article-title":"Early growth of infantile hemangiomas: what parents\u2019 photographs tell us","volume":"130","author":"Tollefson","year":"2012","journal-title":"Pediatrics."},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1016\/j.bjps.2008.03.021","article-title":"Health-related quality of life and impact of haemangiomas on children and their parents","volume-title":"J Plast Reconstr Aesthet Surg","author":"Hoornweg","year":""},{"key":"B20","first-page":"130e3","article-title":"Oral propranolol for treatment of pediatric capillary hemangiomas","volume":"7","author":"Salour","year":"2012","journal-title":"J Ophthalmic Vis Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7199\/ped.oncall.2014.14","article-title":"Use of oral propranolol for treatment of infantile hemangiomas: a case report","volume":"11","author":"Kimmatkar","year":"2014","journal-title":"Pediatr Oncall"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0818-3","article-title":"Vascular lesions of the head and neck: an update on classification and imaging review","volume":"11","author":"Brahmbhatt","year":"2020","journal-title":"Insights Imaging"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1097\/IOP.0000000000001767","article-title":"Risks and benefits of surgical excision of orbital cavernous venous malformations (So-called cavernous hemangioma): factors influencing the outcome","volume-title":"Ophthalmic Plast Reconstr Surg","author":"Strianese","year":"2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40477-020-00443-0","article-title":"The role of ultrasonography in differential diagnosis of orbital lesions","volume":"24","author":"Lanni","year":"2021","journal-title":"J Ultrasound"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001620","article-title":"Upper eyelid isolated arterio-venous malformation treated with embolization in a patient with keloid-prone skin","volume":"36","author":"Capasso","year":"2020","journal-title":"Ophthalmic Plast Reconstructive Surg"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/08820538.2020.1742358","article-title":"Multi-parametric magnetic resonance imaging characterization of orbital lesions: a triple blind study","volume":"35","author":"Russo","year":"2020","journal-title":"Semin Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.15274\/NRJ-2014-10016","article-title":"Coexistence of cavernous hemangioma and other vascular malformations of the orbit: A report of three cases","volume":"27","author":"Strianese","year":"2014","journal-title":"Neuroradiology J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00826-6","article-title":"Orbital venous-lymphatic malformations (lymphangiomas) mimicking cavernous hemangiomas","volume":"131","author":"Selva","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1277e83","DOI":"10.1038\/eye.2011.164","article-title":"The use of propranolol in the management of periocular capillary hemangioma systematic review","volume":"25","author":"Spiteri Cornish","year":"2011","journal-title":"Eye (Lond)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"178e83","DOI":"10.3109\/01676830.2014.884148","article-title":"Propranolol as first-line treatment in orbital infantile hemangiomas: a case series","volume":"33","author":"Levitt","year":"2014","journal-title":"Orbit"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1627e34","DOI":"10.1038\/eye.2011.233","article-title":"Refractive and structural changes in infantile periocular capillary hemangioma treated with propranolol","volume":"25","author":"Snir","year":"2011","journal-title":"Eye (Lond)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2006.01.210","article-title":"Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit","volume":"10","author":"Schwartz","year":"2006","journal-title":"J AAPOS."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"Giese","year":"2015","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-1035","article-title":"LeRoy J death associated with nadolol for infantile hemangioma: A case for improving safety","volume":"145","author":"McGillis","year":"2020","journal-title":"J Pediatrics."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6669383","article-title":"Propranolol for treatment of infantile hemangioma: efficacy and effect on pediatric growth and development","volume":"2021","author":"Giese","year":"2021","journal-title":"Int J Pediatr"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1277e83","DOI":"10.1056\/NEJMoa1404710","article-title":"The use of propranolol in the management of periocular capillary hemangioma systematic review","volume":"25","author":"Spiteri Cornish","year":"2011","journal-title":"Eye (Lond)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"676e81","DOI":"10.1002\/lary.v120:4","article-title":"Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center","volume":"120","author":"Buckmiller","year":"2010","journal-title":"Laryngoscope"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbac006","article-title":"Infantile hepatic hemangiomas: looking backwards and forwards","volume":"5","author":"Gong","year":"2022","journal-title":"Precis Clin Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e31827c6fab","article-title":"Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis","volume":"131","author":"Izadpanah","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0b013e31821ee3a5","article-title":"Preliminary experiences in treating infantile hemangioma with propranolol","volume":"72","author":"Chai","year":"2014","journal-title":"Ann Plast Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2650","article-title":"Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9","volume":"10","author":"Wu","year":"2015","journal-title":"Exp Ther Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S153121","article-title":"Combined oral propranolol with intralesional injection of triamcinolone acetonide in treatment of infantile periocular hemangiomas","volume":"11","author":"Alsmman","year":"2017","journal-title":"Clin Ophthalmol"}],"container-title":["Frontiers in Ophthalmology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1493171\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:10:40Z","timestamp":1746418240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fopht.2025.1493171\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":42,"alternative-id":["10.3389\/fopht.2025.1493171"],"URL":"https:\/\/doi.org\/10.3389\/fopht.2025.1493171","relation":{},"ISSN":["2674-0826"],"issn-type":[{"value":"2674-0826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"article-number":"1493171"}}